Literature DB >> 20413853

Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice.

Peter Holm1, Anders Ettrup, Anders B Klein, Martin A Santini, Mona El-Sayed, Anders B Elvang, Tine B Stensbøl, Jens D Mikkelsen, Gitte M Knudsen, Susana Aznar.   

Abstract

Intrahippocampal injections of aggregated amyloid-beta (Abeta)1-42 in rats result in memory impairment and in reduction of hippocampal 5-HT2A receptor levels. In order to investigate how changes in 5-HT2A levels and functionality relate to the progressive accumulation of Abeta protein, we studied 5-HT2A receptor regulation in double transgenic AbetaPPswe/PS1dE9 mice which display excess production of Abeta and age-dependent increase in amyloid plaques. Three different age-groups, 4-month-old, 8- month-old, and 11-month-old were included in the study. [3H]-MDL100907, [3H]-escitalopram, and [11C]-PIB autoradiography was performed for measuring 5-HT2A receptor, serotonin transporter (SERT), and Abeta plaque levels in medial prefrontal cortex (mPFC), prefrontal cortex (PFC), frontoparietal cortex (FPC), dorsal and ventral hippocampus, and somatosensory cortex. To investigate 5-HT2A receptor functionality, animals were treated with the 5-HT2A receptor agonist DOI and head-twitch response (HTR) subsequently recorded. Expression level of the immediate early gene c-fos was measured by in situ hybridization. We found that the age-related increase in Abeta plaque burden was accompanied by a significant decrease in 5-HT2A receptor binding in mPFC in the 11-month-old group. The changes in 5-HT2A receptor binding correlated negatively with [11C]-PIB binding and were not accompanied by decreases in SERT binding. Correspondingly, 11-month-old transgenic mice showed diminished DOI-induced HTR and reduced increase in expression of c-fos mRNA in mPFC and FPC. These observations point towards a direct association between Abeta accumulation and changes in 5-HT2A receptor expression that is independent of upstream changes in the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413853     DOI: 10.3233/JAD-2010-100117

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

Review 1.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 2.  Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems.

Authors:  Boyi Zong; Fengzhi Yu; Xiaoyou Zhang; Wenrui Zhao; Peng Sun; Shichang Li; Lin Li
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

Review 3.  Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

Authors:  Albert Garcia-Romeu; Sean Darcy; Hillary Jackson; Toni White; Paul Rosenberg
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 4.  Monoaminergic neuropathology in Alzheimer's disease.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

5.  Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study.

Authors:  H N Noristani; R S Meadows; M Olabarria; A Verkhratsky; J J Rodríguez
Journal:  Cell Death Dis       Date:  2011-09-15       Impact factor: 8.469

Review 6.  The serotonergic system and cognitive function.

Authors:  Dubravka Švob Štrac; Nela Pivac; Dorotea Mück-Šeler
Journal:  Transl Neurosci       Date:  2016-05-09       Impact factor: 1.757

Review 7.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

Review 8.  Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.

Authors:  Jaydeep Roy; Ka Chun Tsui; Jonah Ng; Man-Lung Fung; Lee Wei Lim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

Review 9.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

10.  5-HT2A Receptor Binding in the Frontal Cortex of Parkinson's Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study.

Authors:  Nadja Bredo Rasmussen; Mikkel Vestergaard Olesen; Tomasz Brudek; Per Plenge; Anders Bue Klein; Jenny E Westin; Karina Fog; Gitta Wörtwein; Susana Aznar
Journal:  Parkinsons Dis       Date:  2016-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.